Cytori Therapeutics (CYTX) Receiving Somewhat Favorable Media Coverage, Analysis Shows

Press coverage about Cytori Therapeutics (NASDAQ:CYTX) has trended somewhat positive on Wednesday, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cytori Therapeutics earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 47.1469912953141 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:

A number of research analysts have weighed in on the stock. B. Riley reiterated a “hold” rating on shares of Cytori Therapeutics in a research report on Tuesday, November 7th. Zacks Investment Research downgraded shares of Cytori Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Maxim Group set a $5.00 price objective on shares of Cytori Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 11th. Finally, ValuEngine downgraded shares of Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st.

Cytori Therapeutics (CYTX) opened at $0.38 on Wednesday. Cytori Therapeutics has a 1 year low of $0.28 and a 1 year high of $2.13.

Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. The business had revenue of $1.77 million during the quarter, compared to the consensus estimate of $2.04 million. Cytori Therapeutics had a negative net margin of 367.33% and a negative return on equity of 228.21%. During the same quarter in the prior year, the firm posted ($0.26) earnings per share. equities research analysts predict that Cytori Therapeutics will post -0.67 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2017/11/15/cytori-therapeutics-cytx-receiving-somewhat-favorable-media-coverage-analysis-shows.html.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Insider Buying and Selling by Quarter for Cytori Therapeutics (NASDAQ:CYTX)

Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply